Xenetic Biosciences (XBIO)
(Delayed Data from NSDQ)
$3.86 USD
-0.11 (-2.83%)
Updated Sep 23, 2024 02:50 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
XBIO 3.86 -0.11(-2.83%)
Will XBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XBIO
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
XBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ElectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Other News for XBIO
Xenetic reports Q2 EPS (83c) vs. (69c) last year
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences: Q2 Earnings Snapshot
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024